Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

A degradation fragment of type X collagen is a real-time marker for bone growth velocity.

Coghlan RF, Oberdorf JA, Sienko S, Aiona MD, Boston BA, Connelly KJ, Bahney C, LaRouche J, Almubarak SM, Coleman DT, Girkontaite I, von der Mark K, Lunstrum GP, Horton WA.

Sci Transl Med. 2017 Dec 6;9(419). pii: eaan4669. doi: 10.1126/scitranslmed.aan4669.

2.

An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition.

Turner RS, Chadwick M, Horton WA, Simon GL, Jiang X, Esposito G.

Alzheimers Dement (Amst). 2016 Apr 15;4:1-5. doi: 10.1016/j.dadm.2016.03.009. eCollection 2016.

3.

Advances in treatment of achondroplasia and osteoarthritis.

Klag KA, Horton WA.

Hum Mol Genet. 2016 Apr 15;25(R1):R2-8. doi: 10.1093/hmg/ddv419. Epub 2015 Oct 6. Review.

PMID:
26443596
4.

FGFR3 biology and skeletal disease.

Narayana J, Horton WA.

Connect Tissue Res. 2015 Nov;56(6):427-33. doi: 10.3109/03008207.2015.1051224. Epub 2015 Jul 29.

PMID:
26075305
5.

Correlation of the same fields imaged in the TEM, confocal, LM, and microCT by image registration: from specimen preparation to displaying a final composite image.

Keene DR, Tufa SF, Wong MH, Smith NR, Sakai LY, Horton WA.

Methods Cell Biol. 2014;124:391-417. doi: 10.1016/B978-0-12-801075-4.00018-5.

PMID:
25287851
6.

The paracrine feedback loop between vitamin D₃ (1,25(OH)₂D₃) and PTHrP in prehypertrophic chondrocytes.

Bach FC, Rutten K, Hendriks K, Riemers FM, Cornelissen P, de Bruin A, Arkesteijn GJ, Wubbolts R, Horton WA, Penning LC, Tryfonidou MA.

J Cell Physiol. 2014 Dec;229(12):1999-2014. doi: 10.1002/jcp.24658.

7.

FGFR3 targeting strategies for achondroplasia.

Laederich MB, Horton WA.

Expert Rev Mol Med. 2012 Jan 19;14:e11. doi: 10.1017/erm.2012.4. Review.

PMID:
22559284
8.

Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3.

Degnin CR, Laederich MB, Horton WA.

Mol Biol Cell. 2011 Oct;22(20):3861-73. doi: 10.1091/mbc.E11-01-0080. Epub 2011 Aug 24.

9.

The A391E mutation enhances FGFR3 activation in the absence of ligand.

Chen F, Degnin C, Laederich M, Horton WA, Hristova K.

Biochim Biophys Acta. 2011 Aug;1808(8):2045-50. doi: 10.1016/j.bbamem.2011.04.007. Epub 2011 Apr 22.

10.

Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

Laederich MB, Degnin CR, Lunstrum GP, Holden P, Horton WA.

J Biol Chem. 2011 Jun 3;286(22):19597-604. doi: 10.1074/jbc.M110.206151. Epub 2011 Apr 12.

11.

Novel type II collagen reporter mice: New tool for assessing collagen 2α1 expression in vivo and in vitro.

Tryfonidou MA, Lunstrum GP, Hendriks K, Riemers FM, Wubbolts R, Hazewinkel HA, Degnin CR, Horton WA.

Dev Dyn. 2011 Mar;240(3):663-73. doi: 10.1002/dvdy.22569. Epub 2011 Feb 8.

12.

Achondroplasia: pathogenesis and implications for future treatment.

Laederich MB, Horton WA.

Curr Opin Pediatr. 2010 Aug;22(4):516-23. doi: 10.1097/MOP.0b013e32833b7a69. Review.

PMID:
20601886
13.

FGFs in endochondral skeletal development.

Degnin CR, Laederich MB, Horton WA.

J Cell Biochem. 2010 Aug 1;110(5):1046-57. doi: 10.1002/jcb.22629.

PMID:
20564212
14.

Cartilage oligomeric matrix protein promotes cell attachment via two independent mechanisms involving CD47 and alphaVbeta3 integrin.

Rock MJ, Holden P, Horton WA, Cohn DH.

Mol Cell Biochem. 2010 May;338(1-2):215-24. doi: 10.1007/s11010-009-0355-3. Epub 2009 Dec 24.

15.

Crude subcellular fractionation of cultured mammalian cell lines.

Holden P, Horton WA.

BMC Res Notes. 2009 Dec 10;2:243. doi: 10.1186/1756-0500-2-243.

16.

FGFs in endochondral skeletal development.

Horton WA, Degnin CR.

Trends Endocrinol Metab. 2009 Sep;20(7):341-8. doi: 10.1016/j.tem.2009.04.003. Epub 2009 Aug 27. Review.

PMID:
19716710
17.

Confocal/TEM overlay microscopy: a simple method for correlating confocal and electron microscopy of cells expressing GFP/YFP fusion proteins.

Keene DR, Tufa SF, Lunstrum GP, Holden P, Horton WA.

Microsc Microanal. 2008 Aug;14(4):342-8. doi: 10.1017/S1431927608080306.

PMID:
18598569
18.

Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.

Lievens PM, De Servi B, Garofalo S, Lunstrum GP, Horton WA, Liboi E.

Int J Biochem Cell Biol. 2008;40(11):2649-59. doi: 10.1016/j.biocel.2008.05.017. Epub 2008 Jun 5.

PMID:
18577465
19.

Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.

Guo C, Degnin CR, Laederich MB, Lunstrum GP, Holden P, Bihlmaier J, Krakow D, Cho YJ, Horton WA.

Cell Signal. 2008 Aug;20(8):1471-7. doi: 10.1016/j.cellsig.2008.04.001. Epub 2008 Apr 10.

20.

Achondroplasia.

Horton WA, Hall JG, Hecht JT.

Lancet. 2007 Jul 14;370(9582):162-172. doi: 10.1016/S0140-6736(07)61090-3. Review.

PMID:
17630040
21.

International workshop on the Skeletal Growth Plate Stevenson, Washington, June 11-15, 2006.

Horton WA, Tuan RS, Jacenko O.

Matrix Biol. 2007 May;26(4):324-9. Epub 2007 Feb 20. No abstract available.

22.

Developmental biology in orthopaedics. Summary of the 2006 AAOS research symposium.

Alman BA, Horton WA.

J Bone Joint Surg Am. 2007 Mar;89(3):668-71. No abstract available.

PMID:
17332117
23.

BMP action in skeletogenesis involves attenuation of retinoid signaling.

Hoffman LM, Garcha K, Karamboulas K, Cowan MF, Drysdale LM, Horton WA, Underhill TM.

J Cell Biol. 2006 Jul 3;174(1):101-13.

24.

Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling.

Longobardi L, O'Rear L, Aakula S, Johnstone B, Shimer K, Chytil A, Horton WA, Moses HL, Spagnoli A.

J Bone Miner Res. 2006 Apr;21(4):626-36. Epub 2006 Apr 5.

25.

Recent milestones in achondroplasia research.

Horton WA.

Am J Med Genet A. 2006 Jan 15;140(2):166-9. No abstract available.

PMID:
16353253
26.

Secretion of cartilage oligomeric matrix protein is affected by the signal peptide.

Holden P, Keene DR, Lunstrum GP, Bächinger HP, Horton WA.

J Biol Chem. 2005 Apr 29;280(17):17172-9. Epub 2005 Mar 3.

27.

Targeted expression of SHH affects chondrocyte differentiation, growth plate organization, and Sox9 expression.

Tavella S, Biticchi R, Schito A, Minina E, Di Martino D, Pagano A, Vortkamp A, Horton WA, Cancedda R, Garofalo S.

J Bone Miner Res. 2004 Oct;19(10):1678-88. Epub 2004 Jul 12.

28.
29.

Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia.

Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, Horton WA.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):609-14. Epub 2003 Dec 29.

30.

Skeletal development: insights from targeting the mouse genome.

Horton WA.

Lancet. 2003 Aug 16;362(9383):560-9. Review.

PMID:
12932391
31.

A novel insulin-like growth factor (IGF)-independent role for IGF binding protein-3 in mesenchymal chondroprogenitor cell apoptosis.

Longobardi L, Torello M, Buckway C, O'Rear L, Horton WA, Hwa V, Roberts CT Jr, Chiarelli F, Rosenfeld RG, Spagnoli A.

Endocrinology. 2003 May;144(5):1695-702.

PMID:
12697673
32.

The evolving definition of a chondrodysplasia?

Horton WA.

Pediatr Pathol Mol Med. 2003 Jan-Feb;22(1):47-52. Review.

PMID:
12687889
33.

Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Horton WA, Lunstrum GP.

Rev Endocr Metab Disord. 2002 Dec;3(4):381-5. Review. No abstract available.

PMID:
12424440
34.

Col2-GFP reporter mouse--a new tool to study skeletal development.

Cho JY, Grant TD, Lunstrum GP, Horton WA.

Am J Med Genet. 2001 Winter;106(4):251-3.

PMID:
11891675
35.

Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis.

Spagnoli A, Torello M, Nagalla SR, Horton WA, Pattee P, Hwa V, Chiarelli F, Roberts CT Jr, Rosenfeld RG.

J Biol Chem. 2002 May 24;277(21):18860-7. Epub 2002 Mar 8.

36.

Y-position collagen II mutation disrupts cartilage formation and skeletal development in a transgenic mouse model of spondyloepiphyseal dysplasia.

Gaiser KG, Maddox BK, Bann JG, Boswell BA, Keene DR, Garofalo S, Horton WA.

J Bone Miner Res. 2002 Jan;17(1):39-47.

37.

Selective intracellular retention of extracellular matrix proteins and chaperones associated with pseudoachondroplasia.

Vranka J, Mokashi A, Keene DR, Tufa S, Corson G, Sussman M, Horton WA, Maddox K, Sakai L, Bächinger HP.

Matrix Biol. 2001 Nov;20(7):439-50.

PMID:
11691584
38.

Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18. relationship to differentiation stage.

Spagnoli A, Hwa V, Horton WA, Lunstrum GP, Roberts CT Jr, Chiarelli F, Torello M, Rosenfeld RG.

J Biol Chem. 2001 Feb 23;276(8):5533-40. Epub 2000 Nov 10.

39.

Genetic-engineered models of skeletal diseases. II. Targeting mutations into transgenic mice chondrocytes.

Garofalo S, Horton WA.

Methods Mol Biol. 2000;137:491-8. No abstract available.

PMID:
10948562
40.

Col2-GFP reporter marks chondrocyte lineage and chondrogenesis during mouse skeletal development.

Grant TD, Cho J, Ariail KS, Weksler NB, Smith RW, Horton WA.

Dev Dyn. 2000 Jun;218(2):394-400.

41.

LMX1B transactivation and expression in nail-patella syndrome.

Dreyer SD, Morello R, German MS, Zabel B, Winterpacht A, Lunstrum GP, Horton WA, Oberg KC, Lee B.

Hum Mol Genet. 2000 Apr 12;9(7):1067-74.

PMID:
10767331
42.

Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice.

Garofalo S, Kliger-Spatz M, Cooke JL, Wolstin O, Lunstrum GP, Moshkovitz SM, Horton WA, Yayon A.

J Bone Miner Res. 1999 Nov;14(11):1909-15.

44.

Craniofacial and otic capsule abnormalities in a transgenic mouse strain with a Col2a1 mutation.

Maddox BK, Garofalo S, Horton WA, Richardson MD, Trune DR.

J Craniofac Genet Dev Biol. 1998 Oct-Dec;18(4):195-201.

PMID:
10100048
45.

Chondrocyte differentiation in a rat mesenchymal cell line.

Lunstrum GP, Keene DR, Weksler NB, Cho YJ, Cornwall M, Horton WA.

J Histochem Cytochem. 1999 Jan;47(1):1-6.

PMID:
9857207
46.

Cloning, characterization, and chromosomal assignment of the human ortholog of murine Zfp-37, a candidate gene for Nager syndrome.

Dreyer SD, Zhou L, Machado MA, Horton WA, Zabel B, Winterpacht A, Lee B.

Mamm Genome. 1998 Jun;9(6):458-62.

PMID:
9585434
47.

The fate of cartilage oligomeric matrix protein is determined by the cell type in the case of a novel mutation in pseudoachondroplasia.

Maddox BK, Keene DR, Sakai LY, Charbonneau NL, Morris NP, Ridgway CC, Boswell BA, Sussman MD, Horton WA, Bächinger HP, Hecht JT.

J Biol Chem. 1997 Dec 5;272(49):30993-7.

48.

Type II collagen pro-alpha-chains containing a Gly574Ser mutation are not incorporated into the cartilage matrix of transgenic mice.

Maddox BK, Garofalo S, Keene DR, Smith C, Horton WA.

Matrix Biol. 1997 Aug;16(3):93-103.

PMID:
9314159
49.

Fibroblast growth factor receptor 3 and the human chondrodysplasias.

Horton WA.

Curr Opin Pediatr. 1997 Aug;9(4):437-42. Review.

PMID:
9300204
50.

Advances in the genetics of human chondrodysplasias.

Horton WA.

Pediatr Radiol. 1997 May;27(5):419-21. Review. No abstract available.

PMID:
9133354

Supplemental Content

Loading ...
Support Center